参考文献/References:
[1]Liang TJ,Block TM,McMahon BJ,et al.Present and future therapies of hepatitis B:from discovery to cure[J].Hepatology,2015,62(6):1893-1908.[2]Maini MK,Gehring AJ.The role of innate immunity in the immunopathology and treatment of HBV infection[J].J Hepatol,2016,64(1):S60-S70. [3]Gehring AJ,Protzer U.Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection[J].Gastroenterology,2019,156(2):325-337. [4]Altfeld M,Gale M Jr.Innate immunity against HIV-1 infection[J].Nat Immunol,2015,16(6):554-562.[5]Chen X,Qian Y,Yan F,et al.5’-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells[J].Eur J Pharmacol,2013,721(1-3):86-95.[6]Aillot L,Bonnin M,Ait-Goughoulte M,et al.Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells[J].Antimicrob Agents Chemother,2018,62(4):e01741-17.[7]Chen J,Xu W,Chen Y,et al.Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon(IFN)Receptor 1 To Repress IFN/JAK/STAT Signaling[J].J Virol,2017,91(8):e01824-16. [8]Tjwa ET,Zoutendijk R,van Oord GW,et al.Similar frequencies,phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate(TDF)[J].Antiviral Res,2016(132):70-75. [9]Boni C,Vecchi A,Rossi M,et al.TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues[J].Gastroenterology,2018,154(6):1764-1777.[10]Boni C,Lampertico P,Talamona L,et al.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B[J].Hepatology,2015,62(6):1697-1709. [11]Zhang JY,Zou ZS,Huang A,et al.Hyper-activated pro-inflammatory CD16+ monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B[J].PLoS One,2011,6(3):e17484. [12]Wieland S,Thimme R,Purcell RH,et al.Genomic analysis of the host response to hepatitis B virus infection[J].Proc Natl Acad Sci U S A,2004,101(17):6669-6674.[13]Dunn C,Peppa D,Khanna P,et al.Temporal analysis of early immune responses in patients with acute hepatitis B virus infection[J].Gastroenterology,2009,137(4):1289-1300.[14]Zhang E,Lu M.Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection[J].Med Microbiol Immunol,2015,204(1):11-20.[15]Wan Z,Xie G,Wu Y,et al.Cytokines elevated in patients with HBV-related acute-on-chronic liver failure promote NK cell mediated cytotoxicity through TRAIL[J].Dig Liver Dis,2016,48(5):528-535. [16]Liu Y,Cheng LS,Wu SD,et al.IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection[J].Clin Sci,2016,130(11):907-919. [17]Chen P,Xie Q,Lu X,et al.Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA:A community-based study[J].Medicine(Baltimore),2017,96(33):e7766.[18]Milich DR,McLachlan A,Thornton GB,et al.Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site[J].Nature,1987,329(6139):547-549.[19]Harty JT,Tvinnereim AR,White DW.CD8+ T cell effector mechanisms in resistance to infection[J].Ann Rev Immunol,2000(18):275-308. [20]Franzese O,Kennedy PT,Gehring AJ,et al.Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection[J].Virol,2005,79(6):3322-3328.[21]Asabe S,Wieland SF,Chattopadhyay PK,et al.The size of the viral inoculum contributes to the outcome of Hepatitis B virus infection[J].Virol,2009,83(19):9652-9662. [22]Park JJ,Wong DK,Wahed AS,et al.Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B[J].Gastroenterology,2016,150(3):684-695. [23]Bengsch B,Martin B,Thimme R.Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].Hepatol,2014,61(6):1212-1219.[24]Wang S,Zhang,X,Ju, Y,et al.MicroRNA-146a Feedback Suppresses T Cell Immune Function by Targeting Stat1 in Patients with Chronic Hepatitis B[J].Journal of Immunology,2013,191(1):293-301.[25]Cai G,Nie X,Li L,et al.B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function[J].Gastroenterol,2013,48(12):1362-1372. [26]Knolle PA,Thimme R.Hepatic immune regulation and its involvement in viral hepatitis infection[J].Gastroenterology,2014,146(5):1193-1207. [27]Peng H,Li QL,Hou SH,et al.Association of genetic polymorphisms in CD8+T cell inhibitory genes and susceptibility to and progression of chronic HBV infection[J].Infect Genet Evol,2015(36):467-474.[28]Kong X,Sun R,Chen Y,et al.T Cells Drive Myeloid-Derived Suppressor Cell-Mediated CD8+T Cell Exhaustion in Hepatitis B Virus-Induced Immunotolerance[J].Immunol,2014,193(4):1645-1653. [29]Bengsch B,Martin B,Thimme R.Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].Hepatol,2014,61(6):1212-1219. [30]Stoop JN,van der Molen RG,Baan CC,et al.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-777.
相似文献/References:
[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和
生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,31(09):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,31(09):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者
肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute,
Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(09):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[4]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,31(09):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[5]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(09):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[6]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,32(09):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[7]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(09):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[8]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(09):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[9]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[10]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,32(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,32(09):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]